The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
wound infiltration or IM injection
ACH
Little Rock, Arkansas, United States
Frequency and severity of local and systemic adverse events occurring within 14 days of KamRAB treatment
Time frame: Within 14 days from treatment
Frequency and severity of local and systemic SAEs occurring within 84 days of KamRAB treatment
Time frame: Within 84 days of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.